Michigan's Leading Large Urology Group Committed to
Excellence in Patient Care, Research and Education
We are currently updating this page. Please come back again.
Recently diagnosed with prostate cancer? You need to fully understand your diagnosis, prognosis and treatment options.
More aggressive cancers require more aggressive treatment, less require less, or possibly none at all. What is your risk level and what is the best treatment option for you? You need to know.
Comprehensive Medical Center is committed to the most advanced treatment of prostate cancer and is the first, and only, large urology group practice in Michigan to offer cutting-edge prostate cancer prognostic technology — Prostate Px® for recently diagnosed patients and Post-Op Px® for patients who have had surgery.
These new tests analyze your tumor at the cellular and molecular level to help more accurately assess risk. Our pathologists and physicians use the results to help you make personalized, and more informed treatment decisions.
Knowing your Px SCORE® or
can help you make one of
the biggest decisions you will ever make.
Download information on cutting-edge prostate cancer prognostic technology:
Recently Diagnosed with Prostate Cancer?
Recently Had Radical Prostatectomy?
For Referring Physicians
Aureon, Biosciences, Inc.
Prostate Px® and Post-Op® are registered trademarks of Aureon Biosciences, Inc. AureonTM and PostOp Px® are marks owned by Aureon Biosciences, Inc.
* The tests were developed and their performance characteristics determined by Aureon Biosciences, Inc. (Aureon). Clearance or approval of the U.S. Food and Drug Administration was not required for these tests as of the date of this publication. Aureon is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is qualified to perform high-complexity clinical testing. These tests can be used for clinical purposes. These results are adjunctive to the ordering physician’s workup
| Edit Articles